Abstracts Archive - Page 597 of 2425 - ACR Meeting Abstracts

Abstract Number: 0673 • ACR Convergence 2021
The Impact of Allopurinol on Blood Pressure and Renal Outcome in Gout Patients: A Retrospective Study
Aniqa Faraz¹, Sabeeh Islam², Joseph Grisanti³ and Shumaila Iqbal⁴, ¹University at Buffalo-CHS Sisters of Charity, Grand Island, NY, ²Brigham and Women's Hospital Cardiology, Boston, MA, ³Buffalo Rheumatology & Medicine, Orchard Park, NY, ⁴University of Cincinnati, Cincinnati, OH
Background/Purpose: The relationship between change in serum uric acid level and progression of chronic kidney disease and hypertension is still conflicting. In this study, we…
Abstract Number: 0672 • ACR Convergence 2021
Does Obesity Affect Gout Risk Differently Among Genetically Predisposed Individuals?: Sex-Specific Prospective Cohort Study Findings over >32 Years
Chio Yokose¹, Natalie McCormick², Na Lu³, Amit Joshi² and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Two recent analyses of the Global Burden of Disease Study reported on the rising global burden of gout (Safiri A&R 2020, Xia Rheumatology 2020).…
Abstract Number: 0667 • ACR Convergence 2021
Active Screening for Gout Permits Identifying a Larger Cardiovascular Population at High Mortality Risk
Silvia Ruiz-Simón¹, Irene Calabuig², Miguel Gómez-Garberí³ and MARIANO ANDRES⁴, ¹Universidad Miguel Hernández, Alicante, Spain, ²Hospital General Universitario de Alicante, Alicante, Spain, ³Hospital Universitario San Juan de Alicante, San Juan de Alicante, Spain, ⁴Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: We have recently noted by active screening that about a third of gout cases in the cardiovascular population is not registered in records (Calabuig,…
Abstract Number: 0678 • ACR Convergence 2021
Is There a Difference in Self-reported Flare Frequency Between Men and Women?
Naomi Schlesinger¹, Nicholas A Sumpter², Nicola Dalbeth³, Lisa Stamp⁴ and Tony Merriman⁵, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²University of Otago, Dunedin, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand, ⁵University of Alabama at Birmingham, Dunedin, New Zealand
Background/Purpose: There is increasing recognition of gout among women. The postmenopausal rise in serum urate levels in women increases the risk for the development of…
Abstract Number: 0677 • ACR Convergence 2021
Pro-Inflammatory Diet and Increased Risk of Incident Female Gout: 30-Year Prospective Cohort Study of >170,000 Pre- and Post-Menopausal US Women
Natalie McCormick¹, Chio Yokose², Na Lu³, Amit Joshi¹ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Globally, the prevalence of gout is rising in females more than males,1 but data on modifiable risk factors for female gout are scarce. Emerging…
Abstract Number: 0675 • ACR Convergence 2021
Urate-lowering Therapy for Prevention of Gout: Prespecified Analyses from the CKD-FIX Trial
Anushree Tiku¹, Neil Boudville², Fiona Brown³, Alan Cass⁴, Phiilip Clarke⁵, Richard Day⁶, Janak de Zoysa⁷, Bettina Douglas⁸, Randall Faull⁹, David Harris¹⁰, Carmel Hawley¹¹, Graham Jones⁶, John Kanellis³, Elaine Pascoe¹¹, Suetonia Palmer¹², Vlado Perkovic¹³, Gopala Rangan¹⁰, Donna Reidlinger¹¹, Laura Robison¹¹, Robert Walker¹⁴, Giles Walters¹⁵, David Johnson¹¹, Sunil Badve¹³ and Nicola Dalbeth⁷, ¹The George Institute of Australia, Sydney, Australia, ²University of Western Australia, Perth, Australia, ³Monash University, Melbourne, Australia, ⁴Menzies School of Health Research, Darwin, Australia, ⁵University of Oxford, Oxford, United Kingdom, ⁶University of New South Wales, Sydney, Australia, ⁷University of Auckland, Auckland, New Zealand, ⁸Princess Alexandra Hospital, Brisbane, Australia, ⁹University of Adelaide, Adelaide, Australia, ¹⁰University of Sydney, Sydney, Australia, ¹¹University of Queensland, Brisbane, Australia, ¹²University of Otago, Christchurch, New Zealand, ¹³The George Institute for Global Health, Sydney, Australia, ¹⁴University of Otago, Dunedin, New Zealand, ¹⁵The Canberra Hospital, Canberra, Australia
Background/Purpose: The CKD-FIX randomized controlled trial showed that allopurinol did not slow decline of estimated glomerular filtration rate (eGFR) over 104 weeks in patients with…
Abstract Number: 0679 • ACR Convergence 2021
Cardiovascular Risk Associated with Treatment of Allopurinol and Benzbromarone in Patients with Gout
Yeonghee Eun, Seonyoung Kang, Seulkee Lee, Hyungjin Kim, Jaejoon Lee, Eun-Mi Koh and Hoon-Suk Cha, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Background/Purpose: Previous studies have shown that cardiovascular risk is increased in patients with gout. There are many studies on the effect of uric acid lowering…
Abstract Number: 0681 • ACR Convergence 2021
Assessing Patterns of Inpatient Gout Management: Pathway for Optimal Patient Treatment Outcomes
Evan Dombrosky¹, Yashswee KC², Joshua Gavin³, Youssef Roman³ and Nehal Shah³, ¹Virginia Commonwealth University Health System, Glen Allen, VA, ²Loyola University, Oak Park, IL, ³Virginia Commonwealth University Health System, Richmond, VA
Background/Purpose: Gout is the most common inflammatory arthropathy worldwide. Despite having evidence-based guidelines, inconsistent management approaches remain a significant barrier to adequate treatment and prevention.…
Abstract Number: 0680 • ACR Convergence 2021
Gout Stigma: Investigating the Existence of Gout Stigma and Its Impact on Patient Perceptions and Treatment Decisions
N Lawrence Edwards¹, Brian LaMoreaux², Joseph Vitriol³ and Adam Magerman³, ¹University of Florida College of Medicine, Gainesville, FL, ²Horizon Therapeutics plc, Deerfield, IL, ³Horizon Therapeutics, Deerfield, IL
Background/Purpose: Pegloticase is FDA-approved for uncontrolled gout and effectively lowers uric acid levels by conversion of circulating uric acid to allantoin, which is readily removed…
Abstract Number: 0676 • ACR Convergence 2021
Development, Refinement, and Validation of an Emergency Department Gout Flare Electronic Medical Record Alert
Lesley Jackson¹, Narender Annapureddy², Kenneth Saag¹, James Booth³, Giovanna Rosas¹, Jeffrey Foster¹, Amy Mudano¹, Dongmei Sun⁴, John Osborne¹, Tim Bongartz⁵, Erik Hess⁵, Colleen Lawrence⁶, Leah Dunkel⁶ and Maria I. Danila¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Vanderbilt University Medical Center, Nashville, TN, ³Department of Emergency Medicine, University of Alabama School of Medicine, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁵Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁶Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Patients with acute gout are frequently treated in emergency departments (ED) and represent a typically underserved and understudied population. A key limitation of conducting…
Abstract Number: 0670 • ACR Convergence 2021
Hemochromatosis Is Associated with CPPD Through Iron’s Effect on Bone
Jennifer Velasco, Claudia Gohr, Elizabeth MItton-Fitzgerald and Ann Rosenthal, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Hemochromatosis (HH) is one of the strongest known risk factors for calcium pyrophosphate (CPP) crystal deposition. The pathogenic mechanisms causing CPP crystal formation in…
Abstract Number: 0651 • ACR Convergence 2021
Diagnostic Approach to Identifying Small Fiber Neuropathy in Patients with Sarcoidosis
Bassel Bou Dargham¹, Nima Madanchi², Kelsey Satkowiak¹, Huzaefah Syed¹ and Kelly Gwathmey³, ¹Virginia Commonwealth University Medical Center, RICHMOND, VA, ²Virginia CommonHealth University Medical Center, Richmond, VA, ³Virginia Commonwealth University Health system, Richmond, VA
Background/Purpose: Sarcoidosis is a multisystem granulomatous disease that can affect the nervous system in about 5% of patients. Sarcoidosis associated small fiber neuropathy (SSFN) presents…
Abstract Number: 0622 • ACR Convergence 2021
Ethnic Disparities in Giant-Cell Arteritis: A Clinical Comparison Among Caucasian and Hispanic Patients in the Inland Empire of Southern California
Kathleena D'Anna and Mehrnaz Hojjati, Loma Linda University Health, Loma Linda, CA
Background/Purpose: Giant-Cell Arteritis (GCA) is the most common systemic vasculitis among North Americans, historically described in Caucasian populations, with limited clinical data in other ethnic…
Abstract Number: 0559 • ACR Convergence 2021
Targeting NNMT as a Novel Metabolic Approach to Treat Systemic Sclerosis
M.Asif Amin¹, Bo Shi², Pei-Suen Tsou¹, Swarna Bale¹, Phillip Campbell¹, Mikel Gurrea-Rubio¹, Mark Eckert³, Ernst Lengyel³, Johann Gudjonsson⁴ and Varga John¹, ¹University of Michigan, Ann Arbor, MI, ²Nothwestern university, Chicago, IL, ³University of chicago, Chicago, IL, ⁴Department of Dermatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Fibrosis, the hallmark of systemic sclerosis (SSc), is associated with metabolic and epigenetic alterations that are incompletely characterized. Our laboratory had previously implicated dysregulated…
Abstract Number: 0434 • ACR Convergence 2021
Protein Profiling in Pre-dating Samples Separate MPO-ANCA Vasculitis from PR3-ANCA Vasculitis
Mikael Brink¹, Ewa Berglin¹, Aladdin Mohammad², Andrey Alexeyenko³, Kristina Lejon¹ and Solbritt Rantapaa-Dahlqvist⁴, ¹Umeå Universitet, Umeå, Sweden, ²Lund University, Lund, Sweden, ³Karolinska Institutet, Stockholm, Sweden, ⁴Ume University, Umea, Sweden
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is considered a chronic relapsing condition, with unknown etiology. This study was undertaken to gain insight to the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].